Minocycline is a promising candidate as a combination therapy with caspofungin for drug-resistant Candida

Front Cell Infect Microbiol. 2024 Sep 30:14:1452497. doi: 10.3389/fcimb.2024.1452497. eCollection 2024.

Authors

Kazuhiro Itoh^{1

2}, Hiroshi Tsutani¹, Yasuhiko Mitsuke¹, Hiromichi Iwasaki²

Affiliations

¹ Department of Internal Medicine, NHO Awara National Hospital, Awara, Japan.
² Division of Infection Control and Prevention, University of Fukui Hospital, Fukui, Japan.

No abstract available

Keywords: Candida; antifungal drug resistance; caspofungin; minocycline; target of rapamycin proteins.

MeSH terms

Antifungal Agents* / pharmacology
Candida* / drug effects
Candidiasis / drug therapy
Candidiasis / microbiology
Caspofungin* / pharmacology
Caspofungin* / therapeutic use
Drug Resistance, Fungal*
Drug Synergism
Drug Therapy, Combination*
Echinocandins / pharmacology
Humans
Microbial Sensitivity Tests
Minocycline* / pharmacology
Minocycline* / therapeutic use

Substances

Caspofungin
Antifungal Agents
Minocycline
Echinocandins

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.